EGFR and non-small cell lung carcinoma: This multicenter, single-arm, open-label, phase 2 nonrandomized controlled trial including 38 adults found a favorable safety profile of atezolizumab plus bevacizumab, with 51.3% progression-free survival at 12 months and durable responses for patients with advanced nonsquamous NSCLC with high tumor mutation burden and no EGFR or ALK genomic alterations.